{{ card.title }}
{{ card.desc }}
Preclinical Retinal Disease Models and CRO Solutions
Advance retinal research with well-characterized mouse models and integrated ocular imaging, functional, histological, and molecular analysis capabilities.
Integrated Models and Research Capabilities for Retinal Disease Studies
Cyagen’s retinal research platform supports preclinical studies across model development, study design, in vivo execution, longitudinal monitoring, endpoint analysis, and therapeutic evaluation. By combining disease-relevant in vivo systems with standardized workflows and multidisciplinary scientific expertise, we help researchers generate reliable, decision-ready data for retinal disease research and ophthalmic drug development.
{{ item.title }}
{{static_tabs[0].title}}
Explore Inducible and Surgical Models
| Model name | Key Mechanism | Pathology & Clinical Relevance | Action |
|---|---|---|---|
| MNU-Induced Retinitis Pigmentosa Model | Systemic administration of N-methyl-N-nitrosourea (MNU) to induce dose-dependent photoreceptor cell death | Mimics progressive retinal degeneration and visual dysfunction associated with retinitis pigmentosa. | |
| Y79 Cell-Induced Retinoblastoma Model | Subretinal implantation of human Y79 retinoblastoma cells in immunodeficient NKG mice | Recapitulates human intraocular tumor growth and retinal infiltration, supporting the evaluation of anticancer therapies. | |
| Laser-Induced Central Retinal Vein Occlusion Model | Rose bengal administration followed by targeted retinal laser irradiation to induce vascular thrombosis and venous occlusion | Mimics retinal edema, hemorrhage, ischemia, and structural damage associated with central retinal vein occlusion. | |
| Two-Stage Laser-Induced Subretinal Fibrosis Model | Sequential retinal laser treatments on days 0 and 7 to promote sustained inflammation and fibrotic scar formation | Mimics progressive subretinal fibrosis associated with advanced neovascular AMD and polypoidal choroidal vasculopathy. | |
| Laser-Induced Traumatic Optic Neuropathy Model | Targeted Nd laser exposure generates a localized photodisruptive shockwave, inducing focal retinal ganglion cell injury | Recapitulates retinal ganglion cell loss, retinal nerve fiber layer thinning, and impaired visual function associated with traumatic optic neuropathy, supporting the evaluation of neuroprotective and regenerative therapies. |
Discover additional age-related macular degeneration models designed to support AMD pathogenesis research and preclinical therapeutic evaluation.
Relevant Genetic Models
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
|
+
|
Next Page
{{static_tabs[1].title}}
Human iPSC-Derived Retinal Cell Models
Cyagen offers in vitro cell models for retinal disease research, including human iPSC-derived
Retinal Pigment Epithelium (RPE) Cells and gene-edited knockout (KO) cell lines. These models
support retinal disease modeling, gene function studies, and preclinical research. Custom
iPSC-derived and gene-edited cell models are also available to meet specific research needs.
Retinal Pigment Epithelium (RPE) Cell Differentiation
A
B
C
D
E
Figure 1. (A) RPE differentiation workflow. (B) Morphology of cells at days 6, 16, and 42
of differentiation. (C) Immunofluorescence detection of RPE-specific markers (ZO-1, MITF). (D)
qPCR analysis of RPE-specific markers (ZO-1, MITF). (E) Detection of RPE secretory factors
(VEGF, PEDF).
EXPLORE THE iPSC PLATFORM
From Retinal Models to Broader iPSC Applications
Discover Cyagen’s human iPSC platform for retinal, neural, and other disease-relevant applications. The platform integrates iPSC-derived cell models, gene-edited iPSC solutions, and custom development services to support disease modeling, drug discovery, and translational research.
{{static_tabs[2].title}}
Cyagen provides integrated in vivo retinal disease research services that
combine clinically relevant animal models with ocular drug delivery, longitudinal imaging,
visual function testing, and endpoint tissue analysis. This comprehensive platform supports the
evaluation of therapeutic efficacy, retinal protection, disease progression, treatment response,
and potential safety signals across retinal degeneration, retinal vascular disease, ocular
oncology, and subretinal fibrosis studies.
Precision Ocular Drug Delivery for Retinal Studies
Our ophthalmic research team performs specialized ocular administration procedures
for therapies targeting the neural retina, retinal pigment epithelium, vitreous cavity, and
subretinal space. Standardized techniques help improve dosing accuracy, delivery consistency,
and reproducibility across preclinical retinal studies.
Retinal Delivery Routes：
- Intravitreal Injection – direct administration into the vitreous cavity for retinal drugs, biologics, gene therapies, anti-angiogenic agents, and intraocular oncology treatments
- Subretinal Injection – localized delivery between the neural retina and retinal pigment epithelium for therapies targeting photoreceptors, RPE cells, or inherited retinal disorders
In Vivo Retinal Imaging and Functional Readouts
Integrated structural, vascular, functional, histological, and molecular endpoints enable
longitudinal assessment of retinal disease progression and therapeutic response.
{{ tab.kicker }}
{{ tab.title }}
{{ tab.intro }}
{{ tab.support_note }}
{{static_tabs[3].title}}
Cyagen provides integrated ex vivo and post-mortem workflows to define the
cellular, histological, and molecular changes underlying retinal disease and therapeutic
response. Ocular tissue processing, quantitative pathology, spatial biomarker detection, and
molecular assays can be tailored to investigate photoreceptor degeneration, retinal tumors,
vascular injury, inflammation, angiogenesis, and subretinal fibrosis.
| Analysis Category | Specific Services | Key Applications in Retinal Disease Research |
|---|---|---|
| Ocular Tissue Collection and Processing | Precise dissection of the retina, RPE–choroid complex, optic nerve, vitreous, aqueous humor, cornea, lens, iris, choroid, and sclera | Preserve tissue morphology and biomarker integrity for downstream histological, molecular, and PK/PD analyses. |
| Paraffin embedding and frozen section preparation | Generate ocular sections suitable for morphological assessment, protein localization, and quantitative biomarker analysis. | |
| Retinal and RPE–choroid flat-mount preparation | Enable spatial analysis of retinal cells, vascular networks, extracellular matrix deposition, and lesion architecture. | |
| Histopathology and Morphometry | H&E staining | Examine retinal layer integrity, photoreceptor degeneration, edema, tissue disruption, tumor infiltration, and treatment-associated tissue preservation. |
| Quantitative retinal morphometry | Measure outer nuclear layer thickness, total retinal thickness, lesion area, tumor burden, and other disease-relevant structural endpoints. | |
| Pathology scoring | Provide standardized grading of retinal degeneration, inflammation, tissue injury, fibrosis, and therapeutic response. | |
| Spatial Biomarker Analysis | Immunohistochemistry and immunofluorescence | Localize and quantify disease-associated proteins and cellular changes in retinal sections and ocular flat mounts. |
| IB4, collagen I, and α-SMA staining | Assess vascular remodeling, myofibroblast activation, extracellular matrix deposition, and fibrotic lesion formation. | |
| Gene Expression Profiling | qPCR and RT-PCR | Quantify genes associated with retinal degeneration, inflammation, angiogenesis, extracellular matrix remodeling, and fibrosis. |
| Droplet digital PCR (ddPCR) | Enable sensitive absolute quantification of low-abundance transcripts, vector genomes, and biodistribution-related nucleic acid targets. | |
| Protein and Soluble Biomarker Analysis | Western blotting | Evaluate protein expression and signaling pathways associated with disease progression and therapeutic mechanism of action. |
| ELISA | Measure cytokines, growth factors, and secreted biomarkers in ocular tissues and biological fluids. | |
| Cellular Profiling | Flow cytometry and cell sorting | Characterize immune, vascular, tumor, and other ocular cell populations using multiparametric biomarker panels. |
Case Studies
Why Choose Cyagen for Retinal CRO Services?
End-to-End Retinal CRO Support
Integrated services cover model development, study design, in vivo studies, longitudinal monitoring, and endpoint analysis.
Specialized Ocular Drug Delivery
Standardized intravitreal and subretinal administration supports precise and reproducible delivery of retinal therapeutics.
Comprehensive Retinal Readouts
Integrated imaging, functional, histological, and molecular analyses enable multidimensional evaluation of disease progression and therapeutic response.
Disease-Relevant Retinal Models
A broad portfolio of retinal disease models supports customized preclinical studies across diverse indications and therapeutic modalities.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.